drugs of long half life [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2013-04-02 17:34 (4464 d 09:50 ago) – Posting: # 10328
Views: 8,171

Hi John!

❝ The sample size for parallel design (I think Helmut mentioned this to me before, right Helmut? :-)) is based on the total CV (intersubject CV and intrasubject CV).


Yessir.

❝ 90% CI computation will be done using the intersubject CV


Nope. The residual variance in a parallel design is also the total. What Niazi writes:

The width of the confidence interval is determined by the within-subject variance (between-subject variance for parallel group studies) and the number of subjects in the study.

is wrong (or another example of sloppy terminology). In a parallel design between-subject variance is not accessible – only total (or pooled if you prefer).

@Ken:

❝ The comparator product […] reported in their product insert an elimination half-life of 18 days. To fulfill the washout period of 5 half-life, the washout period will be about 90 days.


Don’t fall into the trap of basing you design on a reported mean value. Take the variability into account (i.e., conservatively assume a longer half life). Does the SmPC contain data on the variability (±SD)?

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
25 visitors (0 registered, 25 guests [including 20 identified bots]).
Forum time: 03:24 CEST (Europe/Vienna)

Reach for the stars,
even if you have to stand on a cactus.    Susan Longacre

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5